Chinese Expert Consensus on Pharmacokinetics Guided Treatment for Hemophilia A
Hemophilia A is an X-chromosome-linked recessive genetic disease that lacks coagulation factor Ⅷ (Factor Ⅷ, FⅧ) and is clinically manifested as spontaneous or excessive bleeding after injury.The current main treatment for hemophilia A is alternative infusion of FⅧ, but the fixed infusion mode is sti...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Editorial Office of Journal of Rare Diseases
2022-10-01
|
| Series: | 罕见病研究 |
| Subjects: | |
| Online Access: | https://jrd.chard.org.cn/article/doi/10.12376/j.issn.2097-0501.2022.04.011 |
| _version_ | 1797369873458790400 |
|---|---|
| author | Hemophilia Treatment Center Collaborative Network of China |
| author_facet | Hemophilia Treatment Center Collaborative Network of China |
| author_sort | Hemophilia Treatment Center Collaborative Network of China |
| collection | DOAJ |
| description | Hemophilia A is an X-chromosome-linked recessive genetic disease that lacks coagulation factor Ⅷ (Factor Ⅷ, FⅧ) and is clinically manifested as spontaneous or excessive bleeding after injury.The current main treatment for hemophilia A is alternative infusion of FⅧ, but the fixed infusion mode is still used for the dosage and frequency of infusion, which cannot achieve the optimal curative effect under the principle of individualized treatment.Among the factors that affect the efficacy of FⅧ replacement therapy, the difference in the pharmacokinetics (PK) of FⅧ products by individuals is an important factor.The clinical understanding of individualized FⅧ replacement therapy under the guidance of PK is not sufficient.Therefore, this article reviews the PK characteristics, analysis models, clinical application scenarios and specific treatment plan formulation of FⅧ. |
| first_indexed | 2024-03-08T17:53:17Z |
| format | Article |
| id | doaj.art-7844201bc5b84c8e910cb2d4a594a6b2 |
| institution | Directory Open Access Journal |
| issn | 2097-0501 |
| language | zho |
| last_indexed | 2024-03-08T17:53:17Z |
| publishDate | 2022-10-01 |
| publisher | Editorial Office of Journal of Rare Diseases |
| record_format | Article |
| series | 罕见病研究 |
| spelling | doaj.art-7844201bc5b84c8e910cb2d4a594a6b22024-01-02T06:34:07ZzhoEditorial Office of Journal of Rare Diseases罕见病研究2097-05012022-10-011442843410.12376/j.issn.2097-0501.2022.04.011Chinese Expert Consensus on Pharmacokinetics Guided Treatment for Hemophilia AHemophilia Treatment Center Collaborative Network of ChinaHemophilia A is an X-chromosome-linked recessive genetic disease that lacks coagulation factor Ⅷ (Factor Ⅷ, FⅧ) and is clinically manifested as spontaneous or excessive bleeding after injury.The current main treatment for hemophilia A is alternative infusion of FⅧ, but the fixed infusion mode is still used for the dosage and frequency of infusion, which cannot achieve the optimal curative effect under the principle of individualized treatment.Among the factors that affect the efficacy of FⅧ replacement therapy, the difference in the pharmacokinetics (PK) of FⅧ products by individuals is an important factor.The clinical understanding of individualized FⅧ replacement therapy under the guidance of PK is not sufficient.Therefore, this article reviews the PK characteristics, analysis models, clinical application scenarios and specific treatment plan formulation of FⅧ.https://jrd.chard.org.cn/article/doi/10.12376/j.issn.2097-0501.2022.04.011hemophilia acoagulation factor ⅷpharmacokineticspersonalization |
| spellingShingle | Hemophilia Treatment Center Collaborative Network of China Chinese Expert Consensus on Pharmacokinetics Guided Treatment for Hemophilia A 罕见病研究 hemophilia a coagulation factor ⅷ pharmacokinetics personalization |
| title | Chinese Expert Consensus on Pharmacokinetics Guided Treatment for Hemophilia A |
| title_full | Chinese Expert Consensus on Pharmacokinetics Guided Treatment for Hemophilia A |
| title_fullStr | Chinese Expert Consensus on Pharmacokinetics Guided Treatment for Hemophilia A |
| title_full_unstemmed | Chinese Expert Consensus on Pharmacokinetics Guided Treatment for Hemophilia A |
| title_short | Chinese Expert Consensus on Pharmacokinetics Guided Treatment for Hemophilia A |
| title_sort | chinese expert consensus on pharmacokinetics guided treatment for hemophilia a |
| topic | hemophilia a coagulation factor ⅷ pharmacokinetics personalization |
| url | https://jrd.chard.org.cn/article/doi/10.12376/j.issn.2097-0501.2022.04.011 |
| work_keys_str_mv | AT hemophiliatreatmentcentercollaborativenetworkofchina chineseexpertconsensusonpharmacokineticsguidedtreatmentforhemophiliaa |